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Abstract
Background: AMP-activated protein kinase (AMPK) is a known physiological cellular energy
sensor and becomes phosphorylated at Thr-172 in response to changes in cellular ATP levels.
Activated AMPK acts as either an inducer or suppressor of apoptosis depending on the severity of
energy stress and the presence or absence of certain functional tumor suppressor genes.
Results: Here we show that energy stress differentially affects AMPK phosphorylation and cell-
death in brain tumor tissue and in tissue from contra-lateral normal brain. We compared TSC2
deficient CT-2A mouse astrocytoma cells with syngeneic normal astrocytes that were grown under
identical condition in vitro. Energy stress induced by glucose withdrawal or addition of 2-
deoxyglucose caused more ATP depletion, AMPK phosphorylation and apoptosis in CT-2A cells
than in the normal astrocytes. Under normal energy conditions pharmacological stimulation of
AMPK caused apoptosis in CT-2A cells but not in astrocytes. TSC2 siRNA treated astrocytes are
hypersensitive to apoptosis induced by energy stress compared to control cells. AMPK
phosphorylation and apoptosis were also greater in the CT-2A tumor tissue than in the normal
brain tissue following implementation of dietary energy restriction. Inefficient mTOR and TSC2
signaling, downstream of AMPK, is responsible for CT-2A cell-death, while functional LKB1 may
protect normal brain cells under energy stress.
Conclusion: Together these data demonstrates that AMPK phosphorylation induces apoptosis in
mouse astrocytoma but may protect normal brain cells from apoptosis under similar energy stress
condition. Therefore, using activator of AMPK along with glycolysis inhibitor could be a potential
therapeutic approach for TSC2 deficient human malignant astrocytoma.
Background
AMP-activated protein kinase (AMPK) is a primary regula-
tor of the cellular response to lowered ATP levels in
eukaryotic cells [1,2]. AMPK is a serine/threonine protein
kinase and a member of the Snf1/AMPK protein kinase
family [1]. The activity of AMPK requires phosphorylation
of the alpha subunit on Thr-172 in its activation loop by
one or more upstream kinases (AMPKK) [3-5]. AMPK
phosphorylation down regulates ATP consuming proc-
esses like the synthesis of fatty acids, cholesterol, and pro-
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teins, while up-regulating ATP producing catabolic
pathways like fatty acid oxidation and glucose uptake.
Previous studies indicate that AMPK has both pro and
anti-apoptotic effects on eukaryotic cells [6-16]. The pro-
apoptotic action of activated AMPK is associated with acti-
vation of stress kinases and caspase-3 [7-9,13,17]. In pri-
mary b cells, prolonged stimulation of AMPK induces
apoptosis through an activation of c-Jun-N-terminal
kinase (JNK) [13]. On the other hand, pharmacological
activation of AMPK protects thymocytes from dexametha-
sone-induced apoptosis [11] and Rat-1 fibroblasts from
serum withdrawal induced apoptosis [12].
AMPK is an anti-growth molecule because of its relation-
ship with two tumor suppressor genes: LKB and TSC2
(tuberous sclerosis complex 2). LKB mutations cause
Peutz-Jeghers syndrome, an autosomal dominant disor-
der characterized by multiple hamartomatous polyps in
colon and other parts of the gastrointestinal tract [18-20].
LKB1 is the upstream activating kinase for the stress-
responsive AMP-activated kinase, and provides a link
between regulators of cellular metabolism and cell prolif-
eration in cancer [21]. There are several reports that LKB1
activates AMPK and thus serves as the principal AMPKK
[6,22,23]. LKB1 protects cells from apoptosis in response
to agents that elevate intracellular AMP. LKB1-deficient
mouse embryonic fibroblasts are defective in AMPK acti-
vation and undergo apoptosis under conditions that ele-
vate AMP. Recent observations indicate that Ca2+/
calmodulin – dependent protein kinase kinases also regu-
late AMPK in cell lines lacking expression of LKB1 [24,25].
Under energy stress, AMPK phosphorylates TSC2 on T-
1227 and S-1345 which regulate cell size [26]. Activation
of TSC2 by AMPK- dependent phosphorylation prepares
cells for an unfavorable growth environment and protects
cells from death. Glucose deprivation induces apoptosis
in TSC2-/- and TSC1-/- cells [26]. Since mTOR is a key
downstream target of TSC1/TSC2, inhibition of mTOR by
rapamycin suppresses apoptosis in those cells following
energy depletion [26]. LKB1 may activate TSC2 via the
AMPK [26,27]. mTOR inhibitors have anti-neoplastic
potential since mutations in LKB1, TSC2, or PTEN tumor
suppressor genes produce aberrant mTOR activation in
certain neoplastic conditions [28-31].
Dagon et al [16] recently found that a 40% dietary restric-
tion increased hippocampal AMPK activity, induced neu-
rogenesis, and improved cognition. On the other hand, a
60% dietary restriction over activated AMPK, reduced cog-
nition, and induced neural apoptosis. We show here that
phosphorylation of AMPK at Thr-172 produced apoptosis
in TSC2 deficient CT-2A mouse astrocytoma under 40%
dietary caloric restriction, whereas less AMPK phosphor-
ylation with no apoptosis was seen in contra-lateral nor-
mal brain. This finding was further supported by in vitro
observations where energy stress produced differential
phosphorylation of AMPK in CT-2A cells and in astrocytes
and where phosphorylation of AMPK enhanced apoptosis
in CT-2A cells.
Results
Differential effects of energy stress on ATP depletion, 
AMPK activation and apoptosis in CT-2A tumor cells and 
normal astrocytes in vitro
AMPK is activated by cellular ATP depletion in response to
energy stress. To study energy stress induced ATP deple-
tion and AMPK phosphorylation in the CT-2A tumor cells
and in the control B6 mouse astrocytes, we removed
either glucose and/or glutamine from the media for 24
hours. Since glutamine is the most abundant carbon com-
pound in culture media next to the glucose, we removed
both glucose and glutamine to ensure maximum energy
stress on cells. We found that ATP depletion and AMPK
phosphorylation at Thr-172 was significantly greater in
the CT-2A cells than in the astrocytes under glucose or
glutamine deprivation (Figure 1a, b). This energy stress
also enhanced cleavage of caspase-3 and PARP in CT-2A
cells within 24 hours indicating enhanced apoptosis (Fig-
ure 1b). On the other hand, low AMPK phosphorylation
at Thr-172 was observed in astrocytes after 24 hours under
similar energy stress (Figure 1b).
To determine the number of apoptotic cells, we stained
the cells with Annexin-V, which specifically labels apop-
totic cells. Figure 1c shows that glucose withdrawal
induced apoptosis in 48% of CT-2A cells at 18 hours. A
significant number of astrocytes were found Annexin and
PI positive in the glucose containing medium which could
be due to their high basal turnover rate and confluency.
Glucose withdrawal had no significant effect on apoptosis
in astrocytes. The increased number of living astrocytes
was likely due to decrease in their proliferation rate in glu-
cose free media. Caspase-3 activation in CT-2A cells was
preceded by upstream caspase-9 cleavage after 6 to 8
hours of glucose and glutamine deprived conditions (Fig-
ure 1d). Caspase-9 cleavage was associated with cyto-
chrome c release in the cytosolic part of CT-2A cells in 8
hours of glucose/glutamine free conditions (figure 1e).
Caspase-9 cleavage and cytochrome c was not detected in
astrocytes in the indicated time period (data not shown).
Treatment of CT-2A cells with 3.0 mM glucose caused a
marked elevation of AMPK phosphorylation in 18 hours,
whereas astrocyte was stressed in low glucose condition in
48 hours (Figure 1f). CT-2A cells usually die after 48 hours
with 3.0 mM glucose. Treatment of astrocytes with 3.0
mM glucose caused no AMPK phosphorylation at Thr-172
in 18 hours. AMPK phosphorylation was observed in both
CT-2A and astrocytes following treatment with 2-DG,
which inhibits glucose utilization (Figure 1g and 1h). InMolecular Cancer 2008, 7:37 http://www.molecular-cancer.com/content/7/1/37
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Effects of energy stress on ATP depletion, AMPK phosphorylation and apoptosis in CT-2A and astrocyte cell lines Figure 1
Effects of energy stress on ATP depletion, AMPK phosphorylation and apoptosis in CT-2A and astrocyte cell 
lines. a) Influence of glucose and/or glutamine deprivation on ATP levels in CT-2A astrocytoma and mouse astrocytes. Cells 
were grown in medium with glucose and glutamine. At 0 hour the medium was replaced with fresh medium without glucose 
and glutamine and ATP levels were measured at several time points between 0 and 20 hours. ATP levels are presented as rel-
ative level normalized to ATP levels in control cells that were given fresh medium with glucose and glutamine at 0 hour. b) 
Influence of glucose and/or glutamine deprivation on AMPK phosphorylation and caspase-3 cleavage in CT-2A and astrocytes. 
Cells were treated with different media as indicated for 24 hours. Cell lysates were probed with specific phosphorylated and 
non-phosphorylated antibodies for western blot as indicated. Increased phosphorylation of AMPK in CT-2A cell was evident 
with caspase-3 and PARP cleavage in complete absence of serum, glucose, and glutamine. c) Influence of glucose and/or 
glutamine deprivation on Annexin positive apoptotic cells. Cells were incubated in the presence and absence of glucose and 
glutamine containing media for 18 hours. Cells positive either for Annexin V or for both Annexin V and PI were considered 
early apoptotic and late apoptotic cells, respectively. Glucose/glutamine withdrawal induced apoptosis in 48–50% of CT-2A 
cells but not in astrocytes. d) Influence of glucose and/or glutamine deprivation on caspase 9 cleavage in CT-2A cells. Cells 
were treated with different media as indicated and incubated for 0–8 hours. Cell lysates were probed with anti-caspase 9 for 
western blot. Cleavage of caspase-9 started at 6 hours in complete absence of glucose and/or glutamine. e) Caspase-9 cleavage 
was associated with cytochrome c release at 8 hours in the cytosolic fraction of CT-2A cells. f) Influence of 3.0 mM glucose on 
AMPK phosphorylation in CT-2A and astrocytes. Cells were treated for different hours as indicated. AMPK was maximum 
phosphorylated in CT-2A cells at 18 hours and started dying in 24 hours. AMPK phosphorylation was greater in CT-2A than in 
astrocytes. g) Influence of 2-deoxyglucose (2-DG) on AMPK phosphorylation in CT-2A and astrocytes. Cells were treated with 
50 mM conc. of 2-DG from 0–30 minutes in serum free media. Western blot analysis for phosphorylated AMPK revealed 
increased phosphorylation in CT-2A cells compared to astrocytes. h) Increase in AMPK phosphorylation with time (analyzed 
from g). All experiments were done in triplicate.
c)
e)
b)
a)
f)
d)
g)
h)
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CT-2A, phosphorylation was significantly greater than in
astrocytes following 2-DG treatment. These results indi-
cate that reduced energy substrates produced significantly
greater stress and apoptosis in CT-2A tumor cells than in
normal astrocytes.
AMPK stimulation caused apoptosis in CT-2A cells
To determine the effects of pharmacological stimulation
of AMPK on CT-2A and astrocytes, cells were incubated
with 0.5 and 1.0 mM AICAR in glucose and serum con-
taining medium for 24 hours. AICAR is a cell permeable
drug that is converted to AICAR monophosphate (ZMP)
intracellularly and that mimics the stimulatory effect of
AMP on AMPK. A dose dependent increase in AMPK
phosphorylation at Thr-172 was observed in CT-2A and
astrocytes (Figure 2a) whereas caspase-3 and PARP cleav-
age was observed only in CT-2A cells under normal energy
conditions (figure 2a). Since AICAR was added in normal
growth media, only 8–10% increase in Annexin positive
apoptotic CT-2A cells were observed (Figure 2b). Taken
together, these findings indicate that AMPK phosphoryla-
tion in CT-2A cells is associated with apoptosis.
Differential effects of energy stress on AMPK activation 
and apoptosis in CT-2A brain tumor and normal brain in 
vivo
A 40% dietary caloric restriction (CR) was initiated in B6
mice 48 hours after orthotopic implantation of the CT-2A
tumor in order to determine the effects of energy stress on
AMPK phosphorylation in tumor and contra-lateral nor-
mal appearing brain tissue. Similar to in vitro findings,
AMPK phosphorylation was significantly greater in the
CT-2A tumor than in the normal brain tissue and CR
caused a marked elevation of AMPK phosphorylation in
CT-2A tumor and in normal brain (Figure 3a and 3b).
AMPK phosphorylation was associated with caspase-3
cleavage in tumors, but not in normal brain (Figure 3a). A
significant increase in TUNEL positive cells was found in
CR tumors compared to AL tumors (Figure 3c and 3d). CR
did not induce apoptosis in normal brain tissue. These in
vivo findings support the in vitro findings and suggest that
moderate CR is pro-apoptotic to brain tumors, but not to
normal brain.
Effects of energy stress on the mTOR/S6K protein synthesis 
pathway in CT-2A tumor cells and astrocytes
Protein synthesis is regulated by multiple cellular condi-
tions including cellular energy levels. To determine the
functional significance of AMPK phosphorylation in CT-
2A tumor cells and astrocytes, we examined the mTOR/
S6K protein synthesis pathway. The non-metabolizable
glucose analog 2-DG is a potent glycolytic inhibitor that
mimics the effects of energy starvation. We found that 2-
DG (50 mM) caused a rapid dephosphorylation of mTOR
and S6K in astrocytes and we also show that the dephos-
phorylation of S6K was delayed in CT-2A cells (Figure 4a
and 4b). Furthermore, rapamycin treatment suppressed
glucose deprivation-induced cell-death in the CT-2A cells
(Figure 4c and 4d). Western blot analysis for apoptosis
markers revealed that caspase-3 was cleaved during glu-
cose deprivation in CT-2A and rapamycin treatment sup-
pressed caspase-3 cleavage in CT-2A cells suggesting that
sustained mTOR pathway activity is responsible for CT-2A
cell-death under conditions of energy starvation (Figure
4d). These data, viewed together, indicate that the energy
sensing capability of the mTOR protein synthesis pathway
is less efficient in CT-2A cells than in normal astrocytes.
Role of energy stress on LKB1 expression in normal brain
LKB1 is the major AMPKK that responds to changes in
AMP/ATP ratios. Loss of LKB1 in tumors can increase cell
growth under normal energy conditions, but can enhance
apoptosis under severe energy stress. On the other hand,
LKB1 protects normal cells from apoptosis in response to
elevated intracellular AMP. We observed that LKB1 pro-
tein was expressed in normal brain tissue, but was not
expressed in the CT-2A tumor (Figure 5a). Moreover, CR
significantly increased LKB1 expression in the brain (Fig-
ure 5b). Since CT-2A tumor has no functional LKB1, it is
possible that another AMPKK be responsible for AMPK
activation under energy stress.
Pharmacological stimulation and inhibition of AMPK in 
astrocytes and CT-2A cells
To determine the role of AMPK in cultured cells we treated
both CT-2A and astrocyes with AICAR and compound C
in the low glucose condition. We found that astrocytes
treated with 10 μM of compound C inhibited AMPK
phosphorylation and increased caspase-3 cleavage after
48 hours (Figure 6a). However, compound C treated CT-
2A cells had no protection from cell-death through AMPK
inhibition (data not shown). Since AMPK is a critical
mediator of glycolysis, it is likely that compound C
induced AMPK inhibition further reduced glycolysis in
CT-2A cells under low glucose condition. Therefore we
didn't find any protection in compound C treated CT-2A
cells from apoptosis. On the other hand, astrocytes suf-
fered from both reduced glycolysis and inhibition of
energy conserve signaling from AMPK and resulted in cell-
death. Pharmacological stimulation of astrocytes with
AICAR significantly increased the number of live cells
under severe energy stress (Figure 6b) as detected by cal-
cein staining and fluorescent measurement. Similar treat-
ment to CT-2A cells, the protection was very transient
under severe energy stress (data not shown). Due to
reduced protein synthesis and cellular proliferation,
AICAR treated astrocytes were better protected than CT-2A
cells under severe energy stress condition. These data
strongly suggest that normal astrocytes, due to their func-Molecular Cancer 2008, 7:37 http://www.molecular-cancer.com/content/7/1/37
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tional cell signaling machinery, are well protected from
cell-death under energy stress but not CT-2A cells.
TSC2 expression in CT-2A and astrocytes in vitro and in 
vivo: TSC2 is required for the protection of astrocytes from 
apoptosis under energy stress
Western blot analysis was performed to examine differ-
ences in TSC2 protein expression between CT-2A cells and
Influence of AICAR on AMPK phosphorylation and apoptosis in CT-2A cells Figure 2
Influence of AICAR on AMPK phosphorylation and apoptosis in CT-2A cells. CT-2A and astrocyte cells were 
treated with AICAR (0.5 and 1.0 mM) in glucose, glutamine and serum containing media for 24 hours. a) Cell lysates were 
probed with specific phosphorylated and non-phosphorylated antibodies for western blot as indicated. Dose dependent 
increase in AMPK phosphorylation was evident in CT-2A and astrocytes but caspase-3 and PARP cleavage was noted only in 
AICAR treated CT-2A cells. b) Cells were treated with 1.0 mM AICAR in glucose, glutamine and serum containing media for 
24 hours and treated with Annexin V and PI stain as described in methods. Labeled cells were analyzed by flow cytometry. 8–
10% apoptotic cells were noted in CT-2A cells treated with AICAR compared to untreated cells. No significant cell-death was 
noticed in treated astrocytes. All experiments were done in triplicate.
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syngeneic mouse astrocytes as well as between tumor tis-
sue and contra-lateral normal brain tissue from tumor-
bearing mice. Figure 7a clearly shows that CT-2A tumor
cells are deficient in the TSC2 protein compared with both
astrocytes and normal brain tissue. To directly address the
role of TSC2, as a downstream effector of AMPK, on the
protection of astrocytes from energy stress induced apop-
tosis we treated astrocytes with mouse-specific siRNA that
specifically knocked down the TSC2 gene. Incubation of
astrocytes with 50 and 100 nM of TSC2 siRNA for 24 and
48 hours decreased protein expression by 25 and 50% of
control non-transfected cells, respectively (Figure 7b). The
100 nM concentration was used for the energy stress
experiment. The cells were first treated with 100 nM TSC2
siRNA for 36 hours and the cells were then incubated in
glucose free medium for additional 24 hours. Figure 7c
shows that procaspase-3 expression was reduced by 8–9%
in control astrocytes that were cultured under low glucose
conditions, indicating that the siRNA transfection agent
could induce some death in these cells. Knockdown of
TSC2 expression caused about a 40% reduction in procas-
pase-3 levels compared to control cells, indicating that
Effects of energy stress on AMPK phosphorylation and apoptosis in CT-2A tumor and normal brain Figure 3
Effects of energy stress on AMPK phosphorylation and apoptosis in CT-2A tumor and normal brain. a) Influence 
of 40% dietary caloric restriction on AMPK phosphorylation and caspase-3 cleavage in CT-2A tumor grown orthotopically in 
B6 mice and in contra-lateral normal brain tissue. Tumor implantation, diet administration and collection of tumor and brain 
tissues were described in methods. Tissue lysates were analyzed with indicated antibodies by western blot. Results indicate 
increased AMPK phosphorylation and caspase-3 cleavage in the tumors of CR mice than in AL mice. Normal brain had much 
less AMPK phosphorylation compared to CT-2A tumor. Tissues from 3 independent mice for each group were analyzed. b) 
Ratio of AMPK phosphorylation to total phosphorylation. Asterisk indicates a significant increase in AMPK phosphorylation at 
p < 0.01. c) Influence of 40% dietary caloric restriction on apoptotic cells in CT-2A tumor grown orthotopically. Tumor 
implantation and diet treatment was the same as mentioned above. After 11 day, brain was dissected out and fixed in formalin. 
Paraffin embedded tissue was processed for TUNEL staining. Results indicate that the TUNEL positive apoptotic cells (black 
arrows) are higher in CR tumor than AL tumor. Surrounding normal brain has no significant cell-death. d) Tissues from 3 inde-
pendent mice for each group were analyzed. Apoptotic cell index was significantly higher in CR tumor at p < 0.0001.
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TSC2 knockdown enhanced caspase-3 cleavage and
increased apoptosis under conditions of energy stress.
Overall, data presented in figure 7 suggest that TSC2 defi-
cient astrocytes are more sensitive to death than control
astrocytes under low glucose conditions.
Discussion
Our results indicate that the response of AMPK to energy
stress in brain tumors is fundamentally different from the
response to a similar energy stress in the neural paren-
chyma. Because CT-2A cells are more highly glycolytic
than normal astrocytes, the rate of ATP depletion and
level of AMPK activation was greater in CT-2A cells than
in normal astrocytes. Although the pro-apoptotic and the
anti-apoptotic effects of AMPK are well documented, our
current findings provide novel evidence that activation of
AMPK produces apoptosis in brain tumor tissue and
tumor cells, but prevents apoptosis in normal brain tissue
Effects of energy stress on protein synthesis pathways in CT-2A and astrocytes Figure 4
Effects of energy stress on protein synthesis pathways in CT-2A and astrocytes. a) Influence of energy stress on 
mTOR activity. Cells were treated with 50 mM 2-DG for 0–30 minutes in serum free media. Cell lysates were probed with 
phosphorylated antibodies for mTOR and its substrate S6 kinase. b) Dephosphorylation of mTOR and S6 kinase in astrocytes 
was evident under energy stress condition whereas uncontrolled mTOR activity and delayed S6 kinase dephosphorylation was 
observed in CT-2A cells. c) Influence of rapamycin on low – glucose induced cell-death. CT-2A cells were cultured in 3.0 mM 
glucose containing medium with or without 50 nM rapamycin for 24 hours. Pictures were taken at 24 hours in cell culture. 
Note that the rapamycin treated CT-2A cells had much less floating cells than non-treated cells. Both floating and attaching 
cells were harvested and lysed for western blot assay for caspase – 3. Caspase-3 cleavage was noticed in CT-2A cells in low 
glucose condition which was prevented by rapamycin (d). 
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and astrocytes. Our findings also suggest that LKB1, an up-
stream activator of AMPK, may play a role in the anti-
apoptotic effects of AMPK in normal brain under energy
stress.
The coordination of cellular energy status and survival is
currently a major field of interest in cell biology. Although
both normal brain tissue and brain tumors are highly
dependent on glucose for survival, brain tumors are more
susceptible to the effects of glucose deprivation than nor-
mal brain tissue [32]. AMPK monitors the energy status of
a cell and can initiate appropriate responses to ATP deple-
tion during energy metabolic stress [2,33]. Our current
findings indicate that AMPK phosphorylation is signifi-
cantly greater in CT-2A astrocytoma cells than in normal
astrocytes after 24 hr of glucose deprivation. The
enhanced AMPK phosphorylation is associated with
death in the CT-2A cells, but not in the astrocytes under
normal energy condition. These findings are also consist-
ent with our in vivo observations where a 40% dietary
restriction, which lowers blood glucose levels, caused a
significant elevation of AMPK phosphorylation in both
tumor and in the brain. AMPK phosphorylation was asso-
ciated with caspase 3 cleavage in CT-2A brain tumor, but
not in contra-lateral normal appearing brain tissue.
Previous studies showed that AMPK activation with either
AICAR or low glucose causes apoptosis in cultured rat b
cells or in insulin producing MIN6 cells [13,14]. The pro-
apoptotic effects of AMPK activation in various cancer
cells includes inhibition of fatty acid synthase and induc-
tion of stress kinase and caspase-3 [7-9,14,17]. On the
other hand, AMPK activation also had a protective effect
on stress injured cells in heart ischemia and reperfusion
injury [34,11,35]. In contrast to CT-2A cells under energy
stress where AMPK activation was associated with
enhanced apoptosis, we found that AMPK activation pro-
tected normal astrocytes form apoptosis under energy
stress. This came from findings that compound C, an
inhibitor of AMPK activation, enhanced astrocyte apopto-
sis under energy stress. On the other hand, stimulation of
astrocytes with AMPK stimulator significantly increased
the number of astrocytes under very low glucose condi-
tions. A linkage between the LKB1 and the TSC2 tumor
LKB1 expression in CT-2A tumor and in contra-lateral normal brain and influence of 40%CR Figure 5
LKB1 expression in CT-2A tumor and in contra-lateral normal brain and influence of 40%CR. a) Influence of 40% 
dietary restriction on LKB1 protein expression. CT-2A tumor implantation and diet treatment was the same as mentioned 
above. Endogenous amount of LKB1 was analyzed. CT-2A tumor has no expression for LKB1 whereas normal brain expresses 
it. Moreover, 40% CR increased the expression of LKB1 in normal brain tissue. b) Ratio of LKB1 to β-actin. A significant (p < 
0.05) increase in LKB1 expression has been noticed in the brain of CR mice. Tissues from 3 independent mice were analyzed.
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suppressors may account in part for the apparent opposite
effects of AMPK activation on cell survival and cell-death.
LKB1 is an upstream AMPKK which phosphorylates and
activates AMPK under normal physiological conditions
[6,36]. Mutations of LKB1 occur in Peutz-Jeghers syn-
drome and enhance susceptibility to tumor formation
[18-20]. Shaw et al [6] found that LKB1 deficient cells are
hypersensitive to apoptosis induced by energy stress. On
the other hand, it is essential to protect cells from apopto-
sis in response to agents that elevate intracellular AMP.
The loss of LKB1 in tumors can result in increased cell
growth, but cells lacking LKB1 are resistant to transforma-
tion and readily undergo apoptosis under energy stress
condition [6]. We found that LKB1 is not expressed in CT-
2A tumor tissue, but is expressed in normal brain tissue
contra-lateral to the tumor. We also found that 40% die-
tary restriction caused a significant elevation of LKB1
expression in normal brain tissue. The lack of LKB1 in CT-
2A tumor cells might explain the aberrant growth of these
cells under in vivo and in vitro conditions. Since LKB1 is
absent in CT-2A tumor, other AMPKKs could be responsi-
ble for the stimulation of AMPK under energy stress. Hur-
ley et al [24] investigated other AMPKK in three LKB1
deficient cancer cell lines and found that Ca2+/calmodu-
lin dependent protein kinase kinases regulated AMPK
activity in those cell lines. Rattan et al [37] found that
AMPK can be a potential target for treatment of various
Effects of AMPK phosphorylation in astrocytes Figure 6
Effects of AMPK phosphorylation in astrocytes. a) Astrocytes were cultured with 3.0 mM glucose containing media in 
the presence or absence of 10 μM of compound C for 24 and 48 hours. Treatment with compound C inhibited AMPK phos-
phorylation and increased caspase-3 cleavage in astrocytes. b) Astrocytes were cultured with 1.0 mM glucose containing media 
in the presence or absence of 0.5 and 1.0 mM of AICAR for 72 hours. Treatment with AICAR significantly increased the 
number of astrocytes in a dose dependent manner as detected by fluorescence from calcein labeled astrocytes at p < 0.001.
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cancers independent of the functional tumor suppressor
genes, LKB1. In our findings the presence of LKB1 in nor-
mal brain and induction of apoptosis by inhibiting AMPK
in normal astrocyte potentially suggest that LKB1/AMPK
may play a role in their survival under energy stress.
Cell survival under energy stress is dependent in part on
the ability to conserve energy through inhibition of pro-
tein synthesis. Protein synthesis utilizes approximately
20%–25% of the total cellular energy and is coordinated
with cellular energy status [38]. Activation of AMPK inhib-
its protein synthesis by suppressing the functions of mul-
tiple translation regulators including S6K, 4E-BP1, and
eEF2 in response to energy starvation [26,39]. The mech-
anism of S6K inhibition by AMPK involves the mamma-
lian target of rapamycin (mTOR) pathway [27,40-43]. We
found that 2-DG inhibited both mTOR and S6K phospho-
rylation in normal astrocytes, but not in CT-2A cells. Fur-
thermore, rapamycin treatment suppressed glucose
deprivation induced cell-death in CT-2A cells suggesting
that high mTOR activity is responsible for cell-death
under energy starvation condition. Our results support
the previous findings of Inoki et al [26] who found that
rapamycin treatment suppressed glucose-deprivation
induced cell-death in TSC2 -/- epithelial cells.
Like LKB1, TSC2 is another tumor suppressor gene that
influences protein synthesis downstream of AMPkinase
and upstream of mTOR [26,44,45]. Inoki et al [26] pro-
posed that phosphorylation of TSC2 by AMPK protect
cells from energy deprivation induced cell-death. In our
study, TSC2 knockdown  astrocytes are hypersensitive to
apoptosis under energy stress condition. Absence of both
LKB1 and TSC2 in CT-2A cells well explain the uncon-
trolled mTOR activity and lack of protection from cell-
death under severe energy stress. Shaw et al [27] also
found that LKB1 is required for repression of mTOR under
low ATP conditions in cultured cells in an AMPK and
TSC2 dependent manner and LKB1 mutant mice show
elevated signaling downstream of mTOR. These observa-
tions together with our findings suggest that the LKB1-
AMPK-TSC2-mTOR pathway underlies the adaptive abil-
ity of normal cells to conserve energy when food is scarce.
AMPK has been shown to be a key mediator of glycolysis
[46,47]. Pharmacological stimulation of AMPK with the
AMP analogue AICAR enhances glucose uptake and glyc-
olysis, and inhibition of AMPK with compound C, on the
other hand, reduces glycolysis [48]. This phenomenon is
exemplified in cells deficient in the TSC2 protein. We
show in the current study that the treatment of the TSC2-
deficient CT-2A cells with AICAR increases apoptosis and
is associated with enhanced glycolysis and sustained ele-
vated levels of proliferation when the cells are cultured
under normal glucose (figure 2) or low glucose conditions
(data not shown). Under low glucose conditions, treat-
ment of CT-2A cells with compound C further reduced
glycolysis and therefore we didn't find any rescue from
apoptosis (data not shown). Similarly, normal mouse
astrocytes are not protected from death when cultured
under similar conditions, suggesting that the presence of
an intact AMPK-TSC2-mTOR pathway is necessary for
cells to conserve energy for survival, especially when glyc-
olysis is inhibited (figure 8).
We previously showed that moderate CR (40%) enhanced
apoptosis in experimental mouse and human brain
tumors while enhancing the overall health and vitality of
the tumor-bearing mice [49]. Though the pro-apoptotic
effects of CR in brain tumors occur in large part from
reduced glycolytic energy that tumors rely upon for
growth, its effects on normal brain were not clear. Also,
the molecular mechanisms involved in the global thera-
Expression of TSC2 protein in CT-2A and astrocytes in vitro  and in vivo: Knockdown of TSC2 reduces procaspase-3 expres- sion in astrocytes under energy stress Figure 7
Expression of TSC2 protein in CT-2A and astrocytes 
in vitro and in vivo: Knockdown of TSC2 reduces pro-
caspase-3 expression in astrocytes under energy 
stress. a) Western blot analysis of TSC2 protein expression. 
Two representative samples are shown for each cell and tis-
sue type. CT-2A cells are deficient in TSC2 protein com-
pared to control astrocyte or normal brain. b&c) Astrocytes 
were transfected with siRNA against the mouse TSC2 and 
starved for another 24 hours. Whole cell lysates were ana-
lyzed for procaspase-3 expression. Procaspase-3 was signifi-
cantly decreased indicating increased caspase-3 cleavage and 
apoptosis in TSC2 deficient astrocytes compared to control 
cells under energy stress.
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peutic approach of CR in brain tumors were unknown.
We also proposed that alternative energy fuels like
ketones for the protection of normal brain under energy
stress condition [32]. The bioenergetic transition from
glucose to ketones during CR might have a direct influ-
ence on AMPK activation and cell survival for the normal
brain.
Conclusion
In conclusion, we provide evidence for a dual role of
AMPK activation in the protection of normal brain from
energy stress while also killing the brain tumor cells. Fur-
ther studies are required to better define the role of AMPK
as a potential regulator of energy metabolism and apopto-
sis in normal and tumor tissues.
Methods
Reagents
Phosphorylated and non – phosphorylated
AMPK(Thr172), mTOR(Ser2448), pS6 kinase (Thr389),
caspase-9, caspase-3, PARP, cytochrome-c antibodies,
lysis buffer (10×), and rapamycin (mTOR inhibitor) were
purchased from Cell Signaling, MA. Anti LKB1 was pur-
chased from SantaCruz Biotechnology, CA. β-actin was
purchased from Novus Biologicals, CO. 2 deoxyglucose
(2-DG) from Sigma, MO, AICAR (AMPK stimulator),
compound C (AMPK inhibitor) was from Calbiochem,
CA. Calcein was purchased from Molecular Probe
(Carlsbad, CA).
Cell culture conditions
The CT-2A, mouse astrocytoma cell line was established as
previously described [50]. The C8-D1A, astrocyte cell line
was purchased from American Type Culture Collection
(ATCC), VA. Both CT-2A tumor and astrocyte cell lines
were originated from C57BL/6J mice. Cell lines were
maintained in Dulbecco's modified Eagle's medium
(DMEM) supplemented with 10% fetal bovine serum and
0.5% penicillin/streptomycin (Sigma, St. Louis, MO). The
cells were cultured in a CO2 incubator with a humidified
atmosphere containing 95% air and 5% CO2 at 37°C. For
ATP depletion, the cells were stimulated with 2-DG and
different amount of glucose and glutamine containing
media. For 2-DG treatment, the culture media was
replaced with serum free DMEM containing 6 mM glucose
24 hours before 2-DG stimulation. The cells were then
stimulated with 50 mM of 2-DG that was dissolved in
serum free DMEM for indicated times. For glucose starva-
tion, the cells were pretreated with serum free DMEM for
24 hours and were then cultured with 6.0 mM glucose
and/or 4.0 mM glutamine and, 0 mM glucose and 0 mM
glutamine in serum free DMEM for 24 hours. Addition-
ally, 3.0 mM glucose and 2.0 mM glutamine, 1.0 mM glu-
cose and 0.66 mM of glutamine in serum free DMEM were
used for indicated time.
For rapamycin treatment, CT-2A cells were cultured with
serum free media for 24 hours and were then incubated
with 3.0 mM glucose containing media in the presence or
absence of 20 nM rapamycin for 24 hours. For compound
C treatment, astrocytes were cultured in 3.0 mM glucose
containing media in the presence or absence of 1.0 μM
compound C for 24 and 48 hours. For AICAR treatment,
CT-2A and astrocytes were cultured in 6.0 mM glucose
containing media for 24 hours and in 1.0 mM glucose
containing for 72 hours in the presence and absence of 0.5
and 1.0 mM AICAR.
To harvest cells, the flasks were washed once with phos-
phate buffered saline (PBS) and treated with trypsin-
EDTA for 2 minutes. Cells were gently pipetted off the
flask with PBS, transferred to 15 ml conical centrifuge
tubes, centrifuged for 3 minutes at 1000 rpm, and pellets
were washed again with PBS. Final pelletes were lysed
with lysis buffer and were centrifuged at 8,100 × g for 20
min at 4°C. The lysates were collected and stored at -80°C
for protein analysis. For caspase analysis, both the floating
and the adhered cells were collected and lysed. ATP deter-
mination – Five thousand cells per well were seeded in 96
wells plate and allowed to adhere for 24 hours. Cells were
washed with serum free media and replaced with fresh
media with 6.0 mM glucose and without glucose. ATP lev-
els were measured using the ViaLight Plus kit (Cambrex,
Charlescity, IA) that is based on the bioluminescent meas-
urement of ATP in presence of luciferase, Mg2+ and O2.
Luminescence was measured with a microplate luminom-
eter with an integration time of 5s/well.
siRNA transfection
siRNA against the mouse TSC2 (mouse) was bought from
SantaCruz and they were transfected using Lipofectamine
2000 (Invitrogen, CA). Transfections were carried out
using the concentrations of 50 and 100 nM for 24 and 48
hours. For each experiment astrocytes were grown for 36–
48 hours with siRNA, transfected and control astrocytes
were incubated for additional 24 hours in the presence
and absence of glucose and glutamine and cell lysates
were collected for western blot.
Western Blot Analysis
Tumor cells and tissues were homogenized in ice-cold
lysis buffer (Cell Signaling Technology, MA) containing
20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM
Na2EDTA, 1 mM EGTA, 1% Triton, 2.5 mM NaPPi, 1 mM
α-glycerophosphate, 1 mM Na3 VO4, 1 μg/ml leupeptin,
and 1 mM phenylmethylsufonyl fluoride. Tissue lysates
were transferred to Eppendorf tubes, mixed on a rocker for
1 hr at 4°C, and then centrifuged at 8,100 × g for 20 min.
Supernatants were collected and protein concentrations
were estimated using the Bio-Rad DC protein assay.
Approximately 30–50 μg of total protein from cells andMolecular Cancer 2008, 7:37 http://www.molecular-cancer.com/content/7/1/37
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Possible role of AICAR and compound C on the AMPK pathway and on glycolysis in CT-2A and astrocytes under low glucose  conditions Figure 8
Possible role of AICAR and compound C on the AMPK pathway and on glycolysis in CT-2A and astrocytes 
under low glucose conditions. AICAR stimulates AMPK phosphorylation and glycolysis by increasing glucose uptake in the 
cells. Under low glucose conditions, increased AMP/ATP ratio stimulates AMPK and glycolysis both in astrocytes and CT-2A. 
The presence of an intact TSC2- mTOR signaling pathway in astrocytes helps to reduce protein sysnthesis to conserve energy 
and thus prevents apoptosis. Sustained mTOR-S6 kinase pathway activity enhances apoptosis in TSC2 deficient CT-2A cells 
under low glucose conditions. compound C, on the other hand, inhibits AMPK phosphorylation and glycolysis in the cells. 
Thus, although normal astrocytes downregulate protein synthesis under low glucose conditions as an adaptation to conserve 
energy for survival, the decrease in glycolytic ATP production due to compound C results in increased apoptosis.Molecular Cancer 2008, 7:37 http://www.molecular-cancer.com/content/7/1/37
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10–20 μg of protein from tissues for each sample were
loaded on a 12% SDS-polyacrylamide gel (Bio-Rad, CA)
and electrophoresed. Proteins were transferred to a PVDF
immobilon TM-P membrane (Millipore, MA) overnight at
4°C and blocked in 5% nonfat powered milk in Tris-buff-
ered saline with Tween 20 (pH 7.6) for 3 h. Blots were
then probed with different indicated antibodies overnight
at 4°C with gentle shaking. The blots were then incubated
with appropriate whole horseradish peroxidase-conju-
gated secondary antibody at room temperature. Bands
were visualized using enhanced chemiluminescence plus
system (Amersham, UK). Blots were reprobed with β-actin
antibody used as a loading control.
Measurement of apoptosis by Annexin V staining
CT-2A and astrocyte cells (including floating cells) grown
in 6 well plates were collected following mild trypsiniza-
tion. According to manufacturer's (BD Bioscience,
Pharmingen, CA) protocol, trypsinized cells were washed
once with PBS, and they were resuspended in 100 ul of
Annexin binding buffer mixed with 5 ul of Annexin V flu-
orescein conjugate and propidium Iodide (PI). Resus-
pended cells were incubated at room temperature in the
dark for 15 minutes. Labeled cells were analyzed by FACS
(Beckman coulter, CA).
Mice and experimental brain tumors
Mice of the C57BL/6J (B6) strain were obtained from the
Jackson Laboratory (Bar Harbor, ME). The mice were
propagated in the animal care facility of the Department
of Biology of Boston College, using the animal husbandry
conditions described previously [51]. The syngeneic
mouse brain tumor, CT-2A, was originally produced by
implantation of a chemical carcinogen, 20-methylcholan-
threne, into the brains of B6 mice [50,52]. The CT-2A
tumor arose in the cerebral cortex and was characterized
as a malignant anaplastic astrocytoma [50]. The morpho-
logical, biochemical, and growth characteristics of the CT-
2A brain tumor have been previously described [50]. Male
B6 mice (8–12 weeks of age) were used as tumor recipi-
ents. All animal experiments were carried out with the eth-
ical committee approval in accordance with the National
Institutes of Health Guide for the Care and Use of Labora-
tory Animals and approved by the Institutional Care
Committee.
Brain tumor implantation
Briefly, B6 mice were anaesthetized with Avertin (0.1 ml/
10 g body weight) intra-peritoneally and their heads
shaved and swabbed with 70% ethyl alcohol under sterile
conditions. Small tumor pieces (about 1 mm3, estimated
using a 1 mm × 1 mm grid) from the donor tumor were
implanted into the right cerebral hemisphere of anaesthe-
tized recipient mice as we previously described [49,53].
Caloric restriction
The mice were group housed prior to the initiation of the
experiment and were then separated and randomly
assigned to either a control group that was fed ad libitum
(AL) or to a caloric restricted (CR) group that was fed a
total CR of 40% (60% of the control group). Within each
experiment, the AL-fed and CR-fed mice were matched for
age and body weight. Each mouse was housed singly in a
plastic shoebox cage with a filter top and was given a cot-
ton nesting-pad for warmth. CR was initiated 24 hours
after tumor implantation and was continued for 13 days
after implantation. Total CR maintains a constant ratio of
nutrients to energy, i.e., the average daily food intake
(grams) for the AL fed mice was determined every other
day and the CR-fed mice were given 60% of that quantity
on a daily basis [54,55]. All mice received PROLAB RMH
3000 chow (LabDiet, Purina, Richmond, IN) that con-
tained a balance of mouse nutritional ingredients and
delivered 4.1–4.4 Kcal/g gross energy according to the
manufacturer's specifications. Body weights of all the
mice were recorded every other day.
In situ apoptotic cell detection (TUNEL)
Apoptotic cells were detected using the ApopTag in situ
detection kit TUNEL (terminal deoxynucleotidyl trans-
ferase mediated deoxyuridine triphosphate biotin nick
end labeling) (Oncor, Gaithersberg, MD) as we previously
described [49,55].
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